Oral ketamine in paediatric non-convulsive status epilepticus (Q44580455)

4 December 2017

title

Oral ketamine in paediatric non-convulsive status epilepticus (English)

1 reference

4 December 2017

1 reference

L D Mewasingh

1

1 reference

4 December 2017

T Sékhara

2

1 reference

4 December 2017

A Aeby

3

1 reference

4 December 2017

F J C Christiaens

4

1 reference

4 December 2017

B Dan

5

1 reference

4 December 2017

publication date

1 October 2003

1 reference

Seizure-European Journal of Epilepsy

4 December 2017

published in

1 reference

4 December 2017

volume

12

1 reference

4 December 2017

issue

7

1 reference

4 December 2017

page(s)

483-489

1 reference

Complex partial status epilepticus accompanied by serious morbidity and mortality.

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

Nonconvulsive status epilepticus--a possible cause of mental retardation in patients with Lennox-Gastaut syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

Non-convulsive status epilepticus.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

No, some types of nonconvulsive status epilepticus cause little permanent neurologic sequelae (or: "the cure may be worse than the disease").

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

Refractory status epilepticus: response to ketamine.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

Experimental status epilepticus alters gamma-aminobutyric acid type A receptor function in CA1 pyramidal neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

N-methyl-D-aspartate receptor activation regulates refractoriness of status epilepticus to diazepam

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

Ketamine controls prolonged status epilepticus

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

Chronic elevation of brain GABA levels beginning two days after status epilepticus does not prevent epileptogenesis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

Glutamatergic modulation of GABAergic signaling among hippocampal interneurons: novel mechanisms regulating hippocampal excitability

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

A progressive sequence of electroencephalographic changes during generalized convulsive status epilepticus

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

Progression of electroclinical changes in complex partial status epilepticus: filling in the blanks

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

Self-sustaining status epilepticus: a condition maintained by potentiation of glutamate receptors and by plastic changes in substance P and other peptide neuromodulators

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

NMDA receptor antagonists and limbic status epilepticus: a comparison with standard anticonvulsants

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

Hippocampal Pyramidal Cell Loss in Human Status Epilepticus

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

Ketamine, phencyclidine, and MK-801 protect against kainic acid-induced seizure-related brain damage

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

Pathophysiological mechanisms of brain damage from status epilepticus

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900028-1

7 January 2021

10.1016/S1059-1311(03)00028-1

Identifiers

DOI

1 reference

4 December 2017

1 reference